Dermira Inc. (NASDAQ:DERM) Director William R. Ringo sold 500 shares of the stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $32.30, for a total value of $16,150.00. Following the completion of the transaction, the director now directly owns 500 shares in the company, valued at approximately $16,150. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Dermira Inc. (NASDAQ:DERM) opened at 35.15 on Monday. Dermira Inc. has a one year low of $17.42 and a one year high of $36.34. The stock’s 50 day moving average price is $33.01 and its 200 day moving average price is $31.21. The stock’s market cap is $1.25 billion.

Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.72) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.72). Analysts forecast that Dermira Inc. will post ($3.41) earnings per share for the current year.

Insider Buying and Selling by Quarter for Dermira (NASDAQ:DERM)

Several brokerages have issued reports on DERM. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Leerink Swann reaffirmed a “buy” rating on shares of Dermira in a research report on Wednesday, October 5th. Finally, Needham & Company LLC reaffirmed a “positive” rating and set a $46.00 target price on shares of Dermira in a research report on Monday, October 3rd. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $41.00.

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the last quarter. Glenmede Trust Co. NA purchased a new stake in Dermira during the second quarter valued at approximately $170,000. A.R.T. Advisors LLC purchased a new stake in Dermira during the second quarter valued at approximately $207,000. Morgan Stanley raised its stake in shares of Dermira by 333.1% in the third quarter. Morgan Stanley now owns 6,640 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 5,107 shares during the last quarter. Finally, DIAM Co. Ltd. purchased a new stake in shares of Dermira during the second quarter worth about $231,000. 83.59% of the stock is currently owned by hedge funds and other institutional investors.

About Dermira

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Stock Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related stocks with our FREE daily email newsletter.